National Institutes of Health and COVID-19

Selected news for the healthcare topic - National Institutes of Health, and the healthcare topic - COVID-19 We have 3,670 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
4/15/2021 Sarasota Memorial Hospital kicks off study in search of better weapons against COVID-19 ... COVID-19 patient. "It‚Aos real and it can happen to anybody," she warns. AdvertisementSarasota Memorial Hospital hopes to lead the way in stopping the inflammatory response with a new drug trial studying the use of anti-CD14 monoclonal antibodies.Sponsored and funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, the randomized, double-blind, placebo-controlled study will enroll between ...
4/14/2021 NC COVID-19 April 14 update: Over 2k new cases reported; infection rate stands at 7.6% | WAVY.com ... EDT / Updated: Apr 14, 2021 / 04:37 PM EDTFILE ‚Ai This undated electron microscope image made available by the U.S. National Institutes of Health in February 2020 shows the Novel Coronavirus SARS-CoV-2, yellow ... a serious inflammatory illness linked to the coronavirus had initial COVID-19 infections with no symptoms or only mild ones, new U.S. research shows. (NIAID-RML via AP, File)CHARLOTTE, NC (FOX 46 CHARLOTTE/WAVY ...
4/14/2021 AstraZeneca, Sanguina to develop app for bloodless blood testing | FierceBiotech FierceBiotech ... COVID-19 test with Scanwell HealthHemoglobin is the main protein found in red blood cells, tasked with carrying oxygen throughout the body. Low levels of hemoglobin and red blood cells can result in anemia, and severe cases of anemia can contribute to chronic kidney disease (CKD).According to the National Institutes of Health (NIH), more than one in every seven of the estimated 37 million American adults with CKD ...
4/13/2021 More Than 1 In 10 Children With Covid Are Hospitalized | Kaiser Health News Kaiser Health News ... suffering long covid too, and at least five hospitals are starting clinics.CIDRAP: Study Finds 12% Of US children With COVID-19 Are Hospitalized Among a cohort of 20,714 US children with COVID-19, more ... to help kids with lingering COVID-19 illness as the National Institutes of Health and the Centers for Disease Control and Prevention mount a massive, nationwide study of long-haul COVID that includes children. While ...
4/13/2021 A Mystery Under Study: How, Why And When COVID Vaccines Aren’t Fully Protective NPR ... COVID-19 vaccine when it opened in mid-March. Though some relatively rare cases of coronavirus infection have been documented despite vaccination, "I don't see anything that changes our concept of the vaccine and its efficacy," says Dr. Anthony Fauci of the National Institutes of Health.Ginger Eatman thought she was safe after getting her second COVID-19 vaccination in February. But she kept wearing her mask, using hand sanitizer ...
4/12/2021 Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV‚Ñ¢ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19 PR Newswire ... in collaboration with NIAID to announce results today, both using subcutaneous administration of REGEN-COV in asymptomatic individuals without prior COVID-19 infectionRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced positive data from a Phase ... Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The trial enrolled 204 individuals without any COVID-19 symptoms who tested positive for SARS-CoV-2 but did not ...
4/12/2021 Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV‚Ñ¢ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19 | Markets Insider Business Insider ... in collaboration with NIAID to announce results today, both using subcutaneous administration of REGEN-COV in asymptomatic individuals without prior COVID-19 infection Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive data from a Phase ... Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The trial enrolled 204 individuals without any COVID-19 symptoms who tested positive for SARS-CoV-2 but did not ...
4/12/2021 Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV‚Ñ¢ (casirivimab with imdevimab) | Markets Insider Business Insider ... COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. The trial, which was jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), met its primary and key secondary endpoints, showing that REGEN-COV 1,200 mg administered subcutaneously (SC) reduced the risk of symptomatic infections by 81% in those who were not infected when they entered the ...
4/12/2021 Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV‚Ñ¢ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19 Yahoo News ... in collaboration with NIAID to announce results today, both using subcutaneous administration of REGEN-COV in asymptomatic individuals without prior COVID-19 infectionRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive data from a Phase ... Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The trial enrolled 204 individuals without any COVID-19 symptoms who tested positive for SARS-CoV-2 but did not ...
4/12/2021 Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV(TM) (casirivimab with imdevimab) | 2021-04-12 | Press Releases | Stockhouse ... COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. The trial, which was jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), met its primary and key secondary endpoints, showing that REGEN-COV 1,200 mg administered subcutaneously (SC) reduced the risk of symptomatic infections by 81% in those who were not infected when they entered the ...
4/12/2021 Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV(TM) (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19 | 2021-04-12 | Press Releases | Stockhouse ... in collaboration with NIAID to announce results today, both using subcutaneous administration of REGEN-COV in asymptomatic individuals without prior COVID-19 infectionRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive data from a Phase ... Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The trial enrolled 204 individuals without any COVID-19 symptoms who tested positive for SARS-CoV-2 but did not ...
4/12/2021 Regeneron, Roche injectable antibody drug shows efficacy in preventing Covid-19 MedCity News A Covid-19 antibody cocktail developed by Regeneron Pharmaceuticals and Roche has pivotal clinical trial data showing it protected against the spread of infection among people in the same household. The results support use of the drug as a preventative measure in a formulation that‚Aos easier for both physicians and patients.In the placebo-controlled Phase 3 test, which was conducted with the National Institutes of Health, the main ...
4/12/2021 Regeneron eyes prevention nod for COVID-19 antibody cocktail with simpler injection FiercePharma Regeneron‚Aos Roche-partnered COVID-19 antibody cocktail, already authorized to thwart disease progression in sick patients, has come up with new data showing it can prevent the disease altogether at a lower dose in healthy people.Among healthy individuals who lived with an infected person, the antibody therapy cut the risk of developing symptomatic COVID by 81% in a phase 3 trial jointly run with the National Institutes of ...
4/11/2021 Iowa adds another 432 virus cases, 8 deaths Public Notices CloseThis undated electron microscope image made available by the U.S. National Institutes of Health in February 2020 shows the Novel Coronavirus SARS-CoV-2. Also known as 2019-nCoV, the virus causes COVID-19. The sample was isolated from a patient in the U.S. NIAID-RML via AP Iowa adds another 432 virus cases, 8 deaths Courier staff reports Apr 11, 2021 14 hrs agoThis undated ...
4/9/2021 GE researchers look to put COVID-19-detecting sensors in phones MobiHealthNews Global Edition GE researchers look to put COVID-19-detecting sensors in phones GE Research has received a grant from the NIH to develop sensors that can be embedded into mobile devices to detect COVID ... Research team has received a 24-month grant from the National Institutes of Health to develop miniature sensors that can be embedded into mobile devices in order to detect COVID-19 particles on their surfaces ...
4/9/2021 Fierce Pharma Asia—Takeda-CSL COVID fail; Daiichi Sankyo's new 5-year plan; Legend-J&J CAR-T filing FiercePharma Takeda and CSL closed their COVID-19 alliance after their plasma-derived therapy failed a phase 3 trial by the National Institutes of Health. Daiichi Sankyo laid out its five-year plan covering fiscal 2021 to 2025, featuring nearly $6 billion in sales from cancer drugs. Legend Biotech and Johnson & Johnson wrapped up a rolling submission of their BCMA CAR-T therapy to the FDA, with a possible decision for ...
4/9/2021 Editorial: Fauci's mixed hope, fear messages not helping Boston Herald ... firm as Jell-O.Back in February, the director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health said he was cautiously optimistic about the upcoming MLB season.He ... Americans an update on the state of the fight against COVID-19. ‚AuI want them to know that there is light at the end of the tunnel, particularly that we have multiple, highly efficacious vaccines ...
4/8/2021 Fauci secretly funded gain of function research at Wuhan lab that produced Covid-19 Fauci secretly funded gain of function research at Wuhan lab that produced Covid-19Thursday, April 08, 2021 by: Ethan Huff Bypass censorship by sharing this link: https://www.afinalwarning.com/509764.html Copy URL( Natural News ) Richard H. Ebright, a professor of chemical biology at Rutgers University , says that the National Institutes of Health (NIH) under Anthony Fauci ‚Ausystematically thwarted‚Au proper government oversight of dangerous pathogen research, a move that ...
4/8/2021 Fauci's NIAID awarded the grant that funded Wuhan lab to genetically modify bat-based coronaviruses ... COVID-19).A recent report by the Epoch Times revealed that an oversight board created to scrutinize research that would enhance highly dangerous pathogens did not review a National Institutes of Health (NIH) grant that funded a lab in Wuhan, China to genetically modify bat-based coronaviruses.NIAID, a sub-agency under NIH, awarded the grant to the nonprofit group EcoHealth Alliance to study Chinese bat coronaviruses.The grant apparently ...
4/8/2021 Sound Pharmaceuticals to launch NIH-funded Covid-19 oral therapeutic trial News Sound Pharmaceuticals to launch NIH-funded Covid-19 oral therapeutic trialDeveloped for various neurotologic, neuropsychiatric, and respiratory indications, SPI-1005 is a capsule with a small molecule called ebselen.The latest development comes after Sound Pharmaceuticals received a Cooperative Grant award worth $3.1m from the US National Institutes of Health (NIH) unit National Center for Advancing Translational Sciences (NCATS) for evaluating SPI-1005.Sound Pharmaceuticals co-founder and ...
4/7/2021 Collins, Colleagues Introduce Bipartisan Legislation to Study Impact of Technology and Media on Children US Senate ... Collins joined her colleagues in introducing the Children and Media Research Advancement (CAMRA) Act , bipartisan legislation that would authorize the National Institutes of Health (NIH) to lead a research program on technology and the media ... they need to conduct this important research.‚AuAmid the COVID-19 pandemic, children‚Aos screen time has reportedly increased by 50 percent , and new research shows that one in four young people say they ...
4/7/2021 Icosavax raises $100M to take RSV, COVID-19 vaccines into clinic | FierceBiotech FierceBiotech ... Washington)Icosavax has raised $100 million to study viruslike particle (VLP) vaccines against diseases including respiratory syncytial virus (RSV) and COVID-19. The series B round equips Icosavax to take two assets into clinical trials ... clinic this year. The candidate builds on work by the National Institutes of Health (NIH) on RSV candidate DS-Cav1. Icosavax licensed DS-Cav1, which the NIH put through phase 1, and incorporated it into ...
4/6/2021 Study suggests T-cells don't determine survival in severe COVID-19 19), causes mild to moderate illness in the general population. Some people, however, may experience severe symptoms, which can be potentially fatal.Severe COVID-19 has been tied to T cell lymphopenia, but no causal effect of T cell deficiency on disease severity has been established.Researchers at the Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health found that ...
4/6/2021 NeuroRx Announces Zyesami(TM) (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir | 2021-04-06 | Press Releases | Stockhouse ... PR NewswireRADNOR, Pa. NeuroRx, Inc. reports today that Aviptadil, to be supplied by NeuroRx, has been identified by the National Institutes of Health (NIH) as one of two drugs selected for inclusion in a ... with CO VID-19), is funded by the US Government COVID-19 Therapeutics Response and sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The TESICO protocol has been reviewed and approved as ...
4/6/2021 NeuroRx Announces Zyesami‚Ñ¢ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir-Has-Been-Selected-for-Inclusion-in-NIH-Sponsored-Global-Clinical-Trial-to-Include-Aviptadil-and-Remdesivir?id=296797) ... April 6, 2021 /PRNewswire/ -- NeuroRx, Inc. reports today that Aviptadil, to be supplied by NeuroRx, has been identified by the National Institutes of Health (NIH) as one of two drugs selected for inclusion in a ... with CO VID-19), is funded by the US Government COVID-19 Therapeutics Response and sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The TESICO protocol has been reviewed and approved as ...